Atara Biotherapeutics (ATRA) Current Leases (2019 - 2026)

Atara Biotherapeutics (ATRA) has reported Current Leases for 8 consecutive years, with $1.1 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Current Leases fell 51.07% year-over-year to $1.1 million; the trailing twelve-month figure through Jun 2026 stood at $1.1 million (down 51.07% YoY), and the FY2025 full-year result was $1.0 million, down 92.02% from the prior year.
• Current Leases grew to $1.1 million in Q2 2026 per ATRA's latest filing, from $1.0 million in the prior quarter.
• Across five years, Current Leases topped out at $13.7 million in Q3 2024 and bottomed at $1.0 million in Q1 2026.
• Historically, Current Leases has averaged $8.9 million across 5 years, with a median of $12.1 million in 2023.
• The sharpest annual moves came in 2022 and 2026: Current Leases soared 395.97% in 2022, then plunged 92.11% in 2026.
• Over 5 years, Current Leases stood at $12.8 million in 2022, then retreated by 12.04% to $11.3 million in 2023, then gained by 14.34% to $12.9 million in 2024, then sank by 92.02% to $1.0 million in 2025, then increased by 6.71% to $1.1 million in 2026.
• According to Business Quant data, Current Leases over the past three periods registered $1.1 million, $1.0 million, and $1.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.